Attiq A, Afzal S, Wahab H, Ahmad W, Kandeel M, Almofti Y
Drug Des Devel Ther. 2024; 18:4215-4240.
PMID: 39319193
PMC: 11421457.
DOI: 10.2147/DDDT.S475005.
Vamshidhar I, Rani S, Kalpana M, Gaur A, Umesh M, Ganji V
J Family Med Prim Care. 2023; 12(9):1784-1789.
PMID: 38024874
PMC: 10657079.
DOI: 10.4103/jfmpc.jfmpc_2246_22.
DellIsola G, Dini G, Culpepper K, Portwood K, Ferrara P, Di Cara G
World J Pediatr. 2023; 19(7):635-643.
PMID: 36650407
PMC: 10258176.
DOI: 10.1007/s12519-022-00679-2.
Nakaizumi N, Fukata S, Hirokawa M, Akamizu T
BMJ Case Rep. 2022; 15(12).
PMID: 36455982
PMC: 9716833.
DOI: 10.1136/bcr-2022-252837.
Ando Y, Ono Y, Sano A, Fujita N, Ono S
Am J Trop Med Hyg. 2022; 107(5):1074-1082.
PMID: 36067987
PMC: 9709026.
DOI: 10.4269/ajtmh.21-1223.
A systematic review and meta-analysis of endocrine-related adverse events associated with interferon.
Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K
Front Endocrinol (Lausanne). 2022; 13:949003.
PMID: 35992107
PMC: 9388759.
DOI: 10.3389/fendo.2022.949003.
Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1.
Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H
Int J Clin Oncol. 2022; 27(2):265-280.
PMID: 34973107
PMC: 8816532.
DOI: 10.1007/s10147-021-02081-w.
SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives.
Ruggeri R, Campenni A, Deandreis D, Siracusa M, Tozzoli R, Petranovic Ovcaricek P
Expert Rev Clin Immunol. 2021; 17(7):737-759.
PMID: 34015983
PMC: 8182818.
DOI: 10.1080/1744666X.2021.1932467.
Thyrotoxicosis in patients with COVID-19: the THYRCOV study.
Lania A, Sandri M, Cellini M, Mirani M, Lavezzi E, Mazziotti G
Eur J Endocrinol. 2020; 183(4):381-387.
PMID: 32698147
PMC: 9494315.
DOI: 10.1530/EJE-20-0335.
Dissecting the interaction between COVID-19 and diabetes mellitus.
Chee Y, Tan S, Yeoh E
J Diabetes Investig. 2020; 11(5):1104-1114.
PMID: 32558211
PMC: 7323255.
DOI: 10.1111/jdi.13326.
Case Series: Minocycline-Associated Thyroiditis.
Millington K, Charrow A, Smith J
Horm Res Paediatr. 2019; 92(4):276-283.
PMID: 31533103
PMC: 7078063.
DOI: 10.1159/000502843.
Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang Y, Tseng Y, Chen K, Chen K
BMC Endocr Disord. 2019; 19(1):36.
PMID: 30953492
PMC: 6451221.
DOI: 10.1186/s12902-019-0362-7.
Unravelling the Roles of Susceptibility Loci for Autoimmune Diseases in the Post-GWAS Era.
Ye J, Gillespie K, Rodriguez S
Genes (Basel). 2018; 9(8).
PMID: 30060490
PMC: 6115971.
DOI: 10.3390/genes9080377.
Thyroid dysfunctions secondary to cancer immunotherapy.
Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P
J Endocrinol Invest. 2017; 41(6):625-638.
PMID: 29238906
PMC: 5953760.
DOI: 10.1007/s40618-017-0778-8.
Hashimoto's Thyroiditis and Graves' Disease in One Patient: The Extremes of Thyroid Dysfunction Associated with Interferon Treatment.
Bishay R, Chen R
Case Rep Endocrinol. 2016; 2016:6029415.
PMID: 27042364
PMC: 4793132.
DOI: 10.1155/2016/6029415.
Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y, Kim W, Kwon S, Yu H, Kim J, Choe W
Korean J Intern Med. 2015; 30(6):792-800.
PMID: 26552454
PMC: 4642008.
DOI: 10.3904/kjim.2015.30.6.792.
Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.
Refaat B, El-Shemi A, Ashshi A, Azhar E
Int J Clin Exp Med. 2015; 8(7):10284-303.
PMID: 26379820
PMC: 4565203.
Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.
Zhang R, Shao C, Huo N, Li M, Xi H, Yu M
World J Gastroenterol. 2015; 21(33):9765-73.
PMID: 26361424
PMC: 4562961.
DOI: 10.3748/wjg.v21.i33.9765.
Autoantibodies in chronic hepatitis C: A clinical perspective.
Narciso-Schiavon J, Schiavon L
World J Hepatol. 2015; 7(8):1074-85.
PMID: 26052396
PMC: 4450184.
DOI: 10.4254/wjh.v7.i8.1074.
Thyroid screening in HIV-infected patients with antiretroviral therapy.
Hatzl M, Ollinger A, Geit M, Wiesinger K, Angerbauer K, Aubock J
Wien Klin Wochenschr. 2015; 127(15-16):601-5.
PMID: 25739648
DOI: 10.1007/s00508-015-0733-7.
